An interventional study of Aureobasidium pullulans produced β-glucan and Placebo in Sarcopenia, sponsored by Pusan National University Yangsan Hospital. Completed at 1 site in South Korea. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by Pusan National University Yangsan Hospital · Not applicable, Interventional, and Supportive care
The investigators will conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Aureobasidium pullulans produced β-glucan and regular combined exercise on muscle strength, muscle mass, muscle function, and biomarkers in adults with relative sarcopenia for 12 weeks.
A previous human study has indicated that Aureobasidium pullulans produced β-glucan may increase muscle mass and strength in the elderly. Therefore, the investigators will conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Aureobasidium pullulans produced β-glucan on muscle strength, muscle mass, and muscle function, expanding the target population to adults aged 50 and older with relative sarcopenia, the safety of the compound are also evaluated. The Investigators examine the peak torque/body weight at 60°/s knee extension, handgrip strength, skeletal muscle mass, physical performance, and metabolic parameters at baseline and 12 weeks of intervention. Eighty adults were administered either 1,000 mg of Aureobasidium pullulans produced β-glucan or a placebo each day for 12 weeks.
1,208 studies on the registry are indexed under Sarcopenia; 402 are open to participants now.
This study's enrollment of 116 is above the median of 60 across 775 interventional studies indexed under Sarcopenia.
Browse Sarcopenia studies →Pusan National University Yangsan Hospital is the lead sponsor of 106 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This group takes Aureobasidium pullulans produced β-glucan for 12 weeks.
Dietary Supplement: Aureobasidium pullulans produced β-glucan
This group takes placebo for 12 weeks.
Dietary Supplement: Placebo
Aureobasidium pullulans produced β-glucan 1,000 mg/day for 12 weeks
Placebo 1,000 mg/day for 12 weeks
Muscle strength, 60°/s peak torque (%bodyweight)
60°/s knee extension peak torque (PT) normalized to bodyweight (BW) (PT/BW), right, left, average and 60°/s knee flextion peak torque normalized to body weight (PT/BW), right, left, average
Time frame: 12 weeks
TUG test
Timed Up \& Go test
Time frame: 12 weeks
Appendicular skeletal mass/(height x height)
Using dual-energy X-ray absorptiometry measured at baseline and after 12 weeks
Time frame: 12 weeks
Appendicular skeletal mass/weight x 100
Using dual-energy X-ray absorptiometry measured at baseline and after 12 weeks
Time frame: 12 weeks
Skeletal Muscle Mass Index/(height x height)
Using dual-energy X-ray absorptiometry measured at baseline and after 12 weeks
Time frame: 12 weeks
Hand grip strength, both
Before starting the procedures, the participants were given verbal guidance on how to squeeze the dynamometers to ensure a maximum value. Then, the participants squeezed the dynamometer as hard as possible for three seconds. There were three measurements with 60-second pause intervals between the trials.
Time frame: 12 weeks
Total body fat (%)
Using dual-energy X-ray absorptiometry measured at baseline and after 12 weeks
Time frame: 12 weeks
Truncal body fat (%)
Using dual-energy X-ray absorptiometry measured at baseline and after 12 weeks
Time frame: 12 weeks
Muscle power
The peak power at 60°/s knee extension left, right (Nm/s), and flexion left, right (Nm/s) at baseline and after 12 weeks
Time frame: 12 weeks
Skeletal muscle mass (kg)
Using dual-energy X-ray absorptiometry measured at baseline and after 12 weeks
Time frame: 12 weeks
Short Physical Performance Battery total score
Short Physical Performance Battery total score at baseline and after 12 weeks. The Short Physical Performance Battery (SPPB) total score ranges from a minimum of 0 to a maximum of 12. A higher score indicates better physical performance, while lower scores reflect greater impairment in physical function. The SPPB assesses lower extremity function through balance tests, gait speed, and chair stand tests.
Time frame: 12 weeks
Gait speed (seconds)
Assessed by timing the participants as they walked 2.44 metres at their regular pace at baseline and after 12 weeks
Time frame: 12 weeks
Repeated chair stand test (seconds)
Timed as they completed five sit-to-stand repetitions at baseline and after 12 weeks
Time frame: 12 weeks
EuroQol five dimensional five levels
Index of life quality, minimum, maximum values (0, 1), higher scores mean a better outcome, which will be measured at baseline and after 12 weeks
Time frame: 12 weeks
Concentration of insulin-like growth factor 1
Insulin-like growth factor 1 (ng/mL) measured at baseline and after 12 weeks
Time frame: 12 weeks
Muscle strength, 60°/s peak torque
60°/s knee extension peak torque (PT), right, left, and average and 60°/s knee flexion peak torque (PT), right, left, and average
Time frame: 12 weeks
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pusan National University Yangsan Hospital